PositiveID Corporation (fka PSID)

[AMOTE1]

The $27 Billion Market Most Investors Never Heard Of-- And The Hottest Stocks In The Space
Accesswire
5 minutes ago

????

ONTARIO, CA / ACCESSWIRE / May 17, 2015 / The Wealthy Biotech Trader, an investment newsletter focused on showing everyday Investors new opportunities in little known, rapidly growing Biotech stocks making news and subsequent market moves would like to introduce its #1 pick for Summer.

There are only a few opportunities that present themselves in investing throughout an investor's career. In order to secure these opportunities due diligence (and luck) is at the heart of any success. Today we will feature several companies that are a part of, or related to, the $27 Billion PCR (polymerase chain reaction) and show traders a way to possibly benefit from an opportunity that few are aware of on Wall Street today. [1] PositiveID (PSID) and companies such as ERBA Diagnostics (ERB), Veracyte, Inc. (VCYT), and Applied DNA Sciences (APDN) present investors with an exciting opportunity in a sector of the market that gets little attention, despite the continued upward trend in market valuations of biotech companies as well as the growth of technologies that help identify disease.

For instance, we believe PositiveID (PSID) is a game-changing company/ stock in the molecular diagnostics and testing market with handheld technology called the Firefly Dx that could tap into a $27 billion market to generate significant returns for shareholders. We would like to caution readers of the $27 billion figure as it is representative of the overall "PCR" market, this is made up of many segments. PositiveID (PSID) would be considered part of the "portable, real-time PCR market"-- this particular segment could be valued at up to $5.65 Billion.[2]

The Firefly Dx technology is unique in the marketplace. It offers its users a first-class, handheld testing device for pathogens (SARS, E. coli, Anthrax….). Unlike existing technology, largely in-lab testing, the Firefly Dx is being designed as a lab in the palm of your hand and provides users results in 20 minutes. This can allow rapid action for the treatment of a patient, environment, or a group exposed to the pathogen (Ebola outbreak, Anthrax scare). This product generates interest for homeland security protection, food safety monitoring and first responders like EMS, police and fire departments. Based on our research, The Wealthy Biotech Trader has not seen a competitor that is having the type of success producing rapid (under 20 minutes) PCR results in a point of need device as PositiveID is seeing.

PositiveID (PSID)'s stock after taking a bit of a thrashing last week currently sits at a paltry $4.1 Million market valuation and the stock is currently trading at a very intriguing $0.015, or 1.5 cents.

"The polymerase chain reaction (PCR) is the most powerful technology in molecular biology, enabling researchers to produce millions of copies of specific DNA sequences in a very short duration. The global PCR industry has long been experiencing an upward trend with an accelerating growth rate even during period of recession, thus confirming its positive growth prospects."[3]

We believe that PSID is incredibly undervalued relative to its peers at present levels and could present a substantial opportunity for appreciation for investors. The company provided an update last week about successful testing results with E. coli and we believe continued updates on the Firefly Dx could help drive the market value of the company higher if more investors take note. The company is still identifying applications and markets for the product, which is currently under development.

VCYT, APDN, and ERB are Related Companies in Molecular Diagnostics

PositiveID is not the only beneficiary of technology in molecular diagnostics. There are detection and diagnostic companies like ERBA Diagnostics (ERB) and more pure-play molecular diagnostics stocks like Veracyte Inc. (VCYT).

ERBA Diagnostics had delayed filing its 10-K for 2014, and this was likely weighing significantly on the market valuation, increasing investor's perceived investment risk. On May 6th ERBA Diagnostics appointed Ernesina Scala as Chief Financial Officer and Chandra Krishnan as Senior Vice President Global Sales, Marketing and Business Development.

Veracyte is working in the field of molecular cytology. The company announced on May 12, 2015 that it had issued a study regarding the success of its Percepta Bronchial Genomic Classifier that is used to help patients avoid unnecessary invasive procedures in the treatment of lung cancer. The test identifies smokers at low risk of cancer after an inconclusive bronchoscopy to avoid unnecessary biopsies that are invasive and expensive to the insurance providers. In the 250,000 patients that have a bronchoscopy every year, 40% of results are inconclusive.

The sector is growing rapidly and quarterly results from Applied DNA Sciences (APDN) this week are something to get excited about for future growth prospects. Applied DNA reported 138% sales growth earlier this month as a result of new government contracts. The company provides botanical DNA-based technologies for security and brand protection. The company helps assure what is shipped is authentic or safe.

PositiveID's Firefly Potential

Given the size of this market opportunity, it is not surprising that many of the larger competitors are pursing solutions for rapid, handheld, PCR diagnostics. Based on our research, The Wealthy Biotech Trader has not seen a competitor that is having the type of success producing rapid (under 20 minutes) PCR results in a point of need device as PositiveID is seeing. Furthermore, we can see that even if Firefly Dx only taps a portion of the markets we discussed earlier, the sales potential to PositiveID is significant. Widespread adoption of PSID’s Firefly Dx unit, when fully developed, could help the market valuation of the stock rise.

Given that we believe PSID to be a potentially undervalued stock in this space, more attention could result in a rising market valuation. With a little due diligence investors who take advantage of these opportunities have the potential to experience a massive growth in wealth.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook as well as newswire.

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security's previous day closing price and the high of day price during our promotional coverage.

The Wealthy Biotech Trader's parent company is and will be compensated $25,000 per month by Positive ID. The Wealthy Biotech Trader's controlling parent company has also been compensated $62,500 by PositiveID in the form of a convertible note and readers should understand that we will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.

Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

[1] Axis Research Mind: Citing Sources: [http://www.reportlinker.com/p01254456/Polymerase-Chain-Reaction-PCR-Products-Tools-A-Global-Market-Watch.html]: paragraph, Summary: [June, 2013]

[2] Genetic Engineering and Biotechnology News: Citing Sources: [article http://www.genengnews.com/insight-and-intelligence/pcr-technologies-global-market-forecast-to-2020/77900308/]: paragraph 3: [November 12th, 2014]

[3] Genetic Engineering and Biotechnology News: Citing Sources: [article http://www.genengnews.com/insight-and-intelligence/pcr-technologies-global-market-forecast-to-2020/77900308/]: paragraph 1: [Novemb